Occurrences and Outcomes of Immune Checkpoint Inhibitors-Induced Vitiligo in Cancer Patients: A Retrospective Cohort Study

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

Jacob Schachter, Antoni Ribas, Georgina V. Long et al. · The Lancet · 2017 · 1.2K citations

Open-label Phase 3, Medicine, Melanoma +8

Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab

Camille Hua, Lise Boussemart, Christine Mateus et al. · JAMA Dermatology · 2015 · 638 citations

Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients

Guillermo de Velasco, Youjin Je, Dominick Bossé et al. · Cancer Immunology Research · 2017 · 459 citations · Full text

Vitiligo in Patients with Melanoma

Steven A. Rosenberg, Donald E. White · Journal of Immunotherapy · 1996 · 334 citations

Immunology, Immunoediting, Pathology +18

Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease

François‐Xavier Danlos, Anne-Laure Voisin, Valérie Dyevre et al. · European Journal of Cancer · 2018 · 304 citations

Anti-programmed Death 1, Inflammatory Disease, Autoimmune Disease +13